Pan caspase inhibitor z vad fmk

Primary antibodies against phospho-AKT (S473), pan-AKT, phospho-FoxO3a (S253), totalFoxO3a, phospho-p65 (S276), total-p65, cleaved-caspase3, cleaved-caspase1, cleaved-PARP1, LC3 and p62 were purchased from Cell Signaling Technology (Boston, Massachusetts, USA), total-caspase3, PAR and p-MLKL(S358) was purchased from abcam (Cambridge, UK), p53, PARP1, AIF, pan-AKT, totalFoxO3a, total-p65, GPX4 and β-actin were purchased from proteintech (Wuhan, Hubei, China), Cox IV, H3 and HRP conjugated anti-rabbit/mouse secondary antibodies were purchased from Abbkine (Wuhan, Hubei, China). Lipofectamine 2000 was purchased from Thermo Fisher Scientific (Waltham, Massachusetts, USA). AKT inhibitor SC66, TIC10, autophagy inhibitor CQ, ULK101, pan-caspase inhibitor Z-VAD-FMK and PARP1 inhibitor 3AB were purchased from Selleck (Houston, Texas, USA). CCK-8 kit was from 7 Sea Biotech (Shanghai, China). ROS inhibitor NAC was purchased from Topscience (Shanghai, China).

TI17 was dissolved in dimethyl sulfoxide (DMSO; Sigma, St Louis, MO, USA) and stored at −20°C until use. HDAC inhibitor panobinostat, doxorubicin (DOX) and melphalan (MEL) were obtained from Sigma (S. Louis, MO, USA). Recombinant human interleukin‐6 (IL‐6) was purchased from Biosource, CA, USA. Recombinant human insulin growth factor‐1 (IGF‐1) was obtained from R&D Systems (Minneapolis, MN, USA). Pan‐caspase inhibitor Z‐VAD‐FMK was obtained from Selleckchem (Houston, TX, USA).